Coloplast A/S (OTCMKTS:CLPBY) Stock Jumps 15.2% After Analyst Upgrade

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) shares shot up 15.2% during mid-day trading on Wednesday after Barclays upgraded the stock from a hold rating to a strong-buy rating. The company traded as high as $7.84 and last traded at $7.7750. Approximately 42,445 shares were traded during trading, a decline of 90% from the average session volume of 429,517 shares. The stock had previously closed at $6.75.

Coloplast A/S Trading Down 3.1%

The stock’s fifty day moving average price is $6.85 and its 200 day moving average price is $6.79. The company has a debt-to-equity ratio of 1.51, a current ratio of 1.56 and a quick ratio of 0.94. The stock has a market capitalization of $17.13 billion, a P/E ratio of 36.19, a PEG ratio of 2.85 and a beta of 0.10.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.09. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. Coloplast A/S had a net margin of 10.57% and a return on equity of 42.25%. Research analysts forecast that Coloplast A/S Sponsored ADR will post 0.40 earnings per share for the current year.

Coloplast A/S Company Profile

Coloplast A/S is a Denmark-based medical technology company that develops, manufactures and markets products designed to help people manage intimate health conditions. Its core businesses include ostomy care, continence care, wound and skin care, and interventional urology. The company’s products are used by patients and healthcare professionals in hospitals, clinics and home-care settings.

Coloplast was founded in Denmark in 1957 after nurse Elise Sørensen helped develop an adhesive ostomy bag for her sister, who had undergone surgery.